Skip to content

Join Us
Members Area

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Publication Category: Medications

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

C. W. le Roux; A. Astrup; K. Fujioka; F. Greenway; D. C. W. Lau; L. Van Gaal; R. V. Ortiz; J. P. H. Wilding; T. V. Skjøth; L. S. Manning; X. Pi-Sunyer 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial Lancet
Insulin Resistance & Diabetes

Liraglutide; A new hope for obese diabetics

A. Kumar; D. Kumar; S. Razzaque; A. Kumar; R. Kumar; M. I. Ghauri; M. Yaseen Liraglutide; A new hope for obese diabetics Journal of the Liaquat University of Medical and Health Sciences
Insulin Resistance & Diabetes

In men who are overweight or obese, adding testosterone therapy reduced glucose intolerance/T2DM

T. P. Griffin; S. F. Dinneen In men who are overweight or obese, adding testosterone therapy reduced glucose intolerance/T2DM Ann Intern Med
Insulin Resistance & Diabetes

Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial

D. S. Feig; L. E. Donovan; B. Zinman; J. J. Sanchez; E. Asztalos; E. A. Ryan; I. G. Fantus; E. Hutton; A. B. Armson; L. L. Lipscombe; D. Simmons; J. F. R. Barrett; P. J. Karanicolas; S. Tobin; H. D. McIntyre; S. Y. Tian; G. Tomlinson; K. E. Murphy; D. Fei Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial The Lancet Diabetes and Endocrinology
Insulin Resistance & Diabetes

Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study

P. Behary; G. Tharakan; K. Alexiadou; N. Johnson; N. J. Wewer Albrechtsen; J. Kenkre; J. Cuenco; D. Hope; O. Anyiam; S. Choudhury; H. Alessimii; A. Poddar; J. Minnion; C. Doyle; G. Frost; C. Le Roux; S. Purkayastha; K. Moorthy; W. Dhillo; J. J. Holst; A. Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study Diabetes Care
Insulin Resistance & Diabetes

Study protocol for a double-blind randomised controlled trial investigating the impact of 12 weeks supplementation with a Fucus vesiculosus extract on cholesterol levels in adults with elevated fasting LDL cholesterol who are overweight or have obesity

M. Murray; A. L. Dordevic; K. H. M. Cox; A. Scholey; L. Ryan; M. P. Bonham Study protocol for a double-blind randomised controlled trial investigating the impact of 12 weeks supplementation with a Fucus vesiculosus extract on cholesterol levels in adults with elevated fasting LDL cholesterol who are overweight or have obesity BMJ Open
Cholesterol

Audit of monitoring of the parameters of metabolic syndrome in patients on clozapine

J. Tully; C. Sim; R. Hemani; M. Munir; N. Khalil; S. Fahy Audit of monitoring of the parameters of metabolic syndrome in patients on clozapine Psychiatrist
Metabolic Syndrome

Increased circulating CC chemokine levels in the metabolic syndrome are reduced by low-dose atorvastatin treatment: evidence from a randomized controlled trial

B. V. Loughrey; A. McGinty; I. S. Young; D. R. McCance; L. A. Powell Increased circulating CC chemokine levels in the metabolic syndrome are reduced by low-dose atorvastatin treatment: evidence from a randomized controlled trial Clinical endocrinology
Metabolic Syndrome

Routine screening and rates of metabolic syndrome in patients treated with clozapine and long-acting injectable antipsychotic medications: a cross-sectional study

A. Lydon; J. Vallely; A. Tummon; S. Maher; S. Sabri; J. McLoughlin; A. Liew; C. McDonald; B. Hallahan Routine screening and rates of metabolic syndrome in patients treated with clozapine and long-acting injectable antipsychotic medications: a cross-sectional study Ir J Psychol Med
Metabolic Syndrome

Improving and standardizing metabolic screening for people prescribed antipsychotic medication who are at risk of developing metabolic syndrome within the community mental health setting

D. Hackett; C. Fitzgerald Improving and standardizing metabolic screening for people prescribed antipsychotic medication who are at risk of developing metabolic syndrome within the community mental health setting International journal of mental health nursing
Metabolic Syndrome

Older posts

Newer posts

← Previous Page1 … Page8 Page9 Page10 … Page18 Next →

Search for:

Recent Posts

9th ASOI Annual Conference – Registration now open!
Press Release for World Obesity Day 4th March 2024
ASOI and ICPO response to : Medical Council Communication: “Important medicine shortage information – Ozempic (semaglutide)”
Things to do in Dublin during ECO
ECO 2023 sponsorship update

ASOI

info@asoi.info

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Menu

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Privacy Policy
Site Map

©2024 ASOI